4000-520-616
欢迎来到免疫在线!(蚂蚁淘生物旗下平台)  请登录 |  免费注册 |  询价篮
主营:主营:蛋白纯化试剂,血管和淋巴管研究试剂
咨询热线电话
4000-520-616
当前位置: 首页 > 产品中心 > cellular_metabolism > Relia Tech/Human B7-2 Fc, soluble/100 µg/S01-007
商品详细Relia Tech/Human B7-2 Fc, soluble/100 µg/S01-007
Relia Tech/Human B7-2 Fc, soluble/100 µg/S01-007
Relia Tech/Human B7-2 Fc, soluble/100 µg/S01-007
商品编号: S01-007
品牌: reliatech
市场价: ¥3400.00
美元价: 2040.00
产地: 美国(厂家直采)
公司:
产品分类: 细胞代谢
公司分类: cellular_metabolism
联系Q Q: 3392242852
电话号码: 4000-520-616
电子邮箱: info@ebiomall.com
商品介绍
Cat-Nr.S01-007
Size100 µg
Price170 €
SourceCHO cells
LabelFc-tag
Formulationlyophilized
Purity Confirmation> 95% by SDS-PAGE & HPLC analyses
Length [aa]453
Molecular Weight51.2 kDa
Endotoxin Levels< 0.1 ng/µg of protein (<1EU/µg)
Biological ActivityDetermined by its ability to inhibit alkaline phosphatase activity in differentiating MC3T3/E1 cells. The expected ED50 for this effect is 0.5-1.5 μg/ml.
Species ReactivityHuman
SynonymsB70, CD86, ETC1
DescriptionB7-1 and B7-2 are transmembrane glycoproteins of the immunoglobulin superfamily that are expressed, along with the receptors CD28 and CTLA4, by antigen-presenting cells, and along with these receptors, constitute crucial co-stimulatory pathways for T and B cell regulatory responses. As members of the B7 family, B7-1 and B7-2 play principal roles in immunity, activating immune response and maintaining immune tolerance through engagement with CD28 and CTLA4. Co-stimulatory signals generated by B7-1 and B7-2 interactions with CD28 serve to stimulate T cell activation and prevent anergy through the amplification of T cell receptor (TCR) signaling. In contrast, interactions of the ligands with CTLA-4 serves to maintain T cell homeostasis and self-tolerance through the disruption of stimulatory signaling from B7 isoform bound CD28 complexes, and by inducing powerful inhibitory signals in T cells. B7-1 plays an important role in immune response through its amplification and regulation of T cell activity at peripheral inflammation sites. B7-1, like CTLA-4, is, however, only poorly expressed on resting dendritic cells, and its up-regulation is, therefore, considerably delayed upon immune activation. Conversely, B7-2 and CD28 are constitutively expressed by resting hematopoietic and T cells, respectively, and as a result are able to rapidly induce up-regulation upon immune activation, making them critical to the early co-stimulatory signaling of immune response. Both B7-1 and B7-2 have been shown to demonstrate co-stimulatory activity in T-cell proliferation in vitro and elicit enhanced antitumor immune response in vivo. Recombinant Human B7-2Fc is a homodimeric B7-2 fusion protein, whose monomer contains a total of 453 amino acid residues, consisting of 222 amino acid residues corresponding to the extracellular domain of human B7-2, fused to the Fc portion of human IgG1. The calculated molecular weight of the B7-2 Fc monomer is 51.2 kDa.
Protein SequenceLKIQAYFNET ADLPCQFANS QNQSLSELVV FWQDQENLVL NEVYLGKEKF DSVHSKYMGR TSFDSDSWTL RLHNLQIKDK GLYQCIIHHK KPTGMIRIHQ MNSELSVLAN FSQPEIVPIS NITENVYINL TCSSIHGYPE PKKMSVLLRT KNSTIEYDGV MQKSQDNVTE LYDVSISLSV SFPDVTSNMT IFCILETDKT RLLSSPFSIE LEDPQPPPDH GGPKSCDKTH TCPPCPAPEL LGGPSVFLFP PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS NKALPAPIEK TISKAKGQPR EPQVYTLPPS RDELTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS CSVMHEALHN HYTQKSLSLS PGK
Uniprot IDP42081
Protein RefSeqNP_795711.1
mRNA RefSeqNM_176892.1
品牌介绍
Receptor Ligand Technologies GmbH 公司(RELIA Tech )位于德国不伦瑞克,是一家后基因组生物技术公司,该公司运用独特的技术专注于受体和配体的发现与研究,从而使商业化,产品广泛使用于科学研究,实验诊断和临床应用。瑞莱技术的灵活性和竞争力必将使其在这个快速整合的功能基因组学和蛋白组学的新时代发展壮大.RELIA公司提供的细胞因子,生长因子,重组蛋白产品一致内毒素检测项目,且内毒素水平非常低。 受体配体技术有限公司(RELIATech)是一家后基因组生物技术公司,致力于在配体与受体相互作用领域的新技术和新产品的发现和商业化,用于研究,诊断和临床领域。该公司位于德国不伦瑞克,由以下公司成立于2000年10月: 阿夫纳·亚永教授以色列魏兹曼科学研究所(WIS) 赫伯特·韦奇博士德国生物技术德国研究中心(GBF) Bernhard Barleon博士德国肿瘤生物学诊所(KTB) 创始人是从事细胞生长因子相互作用,酪氨酸激酶及其信号传导途径(涉及组织重塑,体内平衡和疾病)领域的细胞和分子生物学家,工作时间超过10年。特别是Herbert A. Weich博士和Bernhard Barleon博士从事血管生成,肿瘤血管生成和实体瘤进展领域的基础研究。    诸如“生长因子和细胞因子”之类的信号蛋白,连同其跨膜/“可溶性受体”和相关的激酶,在生理和病理生理条件下都作为关键的调节分子参与了所有高级生物的发育和功能。这些多肽调节细胞分化,组织重塑和体内平衡,并在各种疾病状态下被失调。由人类基因组计划编码新信号蛋白的新生长调节基因的发现,以及对它们功能的阐明,无疑将是未来十年的主要挑战之一。 RELIATech的使命是开发和商品化在“受体和配体相互作用”领域中有用的新产品,用于基础研究,药物开发和临床社区。RELIATech的灵活性和能力必将使其在功能基因组学和蛋白质组学的新时代迅速整合和扩展。